Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E33.91 EPS (ttm)2.21 Insider Own0.08% Shs Outstand2.60B Perf Week0.23%
Market Cap194.46B Forward P/E15.88 EPS next Y4.71 Insider Trans-45.56% Shs Float2.60B Perf Month3.05%
Income5.95B PEG3.56 EPS next Q1.05 Inst Own78.00% Short Float2.88% Perf Quarter8.31%
Sales41.73B P/S4.66 EPS this Y29.20% Inst Trans0.64% Short Ratio7.26 Perf Half Y26.38%
Book/sh12.18 P/B6.14 EPS next Y8.48% ROA3.90% Target Price79.12 Perf Year38.23%
Cash/sh3.96 P/C18.91 EPS next 5Y9.54% ROE10.10% 52W Range52.83 - 76.61 Perf YTD32.89%
Dividend2.20 P/FCF51.63 EPS past 5Y-1.90% ROI8.70% 52W High-2.38% Beta0.72
Dividend %2.94% Quick Ratio1.20 Sales past 5Y-3.20% Gross Margin67.40% 52W Low41.57% ATR1.63
Employees69000 Current Ratio1.40 Sales Q/Q4.50% Oper. Margin17.80% RSI (14)56.74 Volatility2.01% 2.48%
OptionableYes Debt/Eq0.73 EPS Q/Q- Profit Margin8.00% Rel Volume0.91 Prev Close74.78
ShortableYes LT Debt/Eq0.61 EarningsOct 25 BMO Payout152.00% Avg Volume10.30M Price74.79
Recom1.80 SMA201.65% SMA503.89% SMA20018.28% Volume2,826,892 Change0.01%
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Nov-21-18 10:04AM  Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility Zacks
09:58AM  IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance Zacks
09:44AM  FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz Zacks
09:36AM  Shire-Takeda Deal Gets Phase I Conditional European Approval Zacks
08:58AM  TESARO Shares Rally on Rumors of Potential Acquisition Offer Zacks
08:55AM  Amid sell-off, top analysts are getting bullish these 5 defensive stocks including Merck CNBC
08:16AM  Can Deal Interest Help Tesaro Recover? Motley Fool
07:05AM  Today's Research Reports on Trending Tickers: Johnson & Johnson and Merck & Co. ACCESSWIRE
Nov-20-18 06:54PM  UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium GlobeNewswire
08:12AM  Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails Zacks
Nov-19-18 03:23PM  3 Steady Healthcare Stocks to Hold During a Downturn InvestorPlace
09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
09:35AM  Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs Zacks
07:12AM  Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer PR Newswire
06:30AM  BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium GlobeNewswire
Nov-17-18 05:02PM  Better Buy: Celgene Corporation vs. Merck & Co. Motley Fool
Nov-16-18 08:35AM  Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings Zacks
06:16AM  A Look At Merck & Co Incs (NYSE:MRK) Exceptional Fundamentals Simply Wall St.
Nov-15-18 04:09PM  Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug Zacks
10:01AM  Merck's Keytruda Improves Survival in Esophageal Cancer Study Zacks
09:50AM  MARKETS: Stocks could bounce here, but I'm selling the rally Yahoo Finance Video
Nov-14-18 05:50PM  Merck (MRK) Stock Moves -0.7%: What You Should Know Zacks
03:34PM  AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study Zacks
10:15AM  Merck Starts Rolling BLA Submission for Ebola Vaccine V920 Zacks
09:07AM  Can These 2 Battered Biotech Stocks Recover? Motley Fool
08:17AM  The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut Benzinga
07:15AM  Merck drug Keytruda succeeds in late-stage esophageal cancer trial Reuters
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS 10) Business Wire
06:19AM  Dont Be Fooled by the Recent Selling; Hedge Funds Still Love Merck & Co., Inc. (MRK) Insider Monkey
Nov-13-18 05:20PM  Daniel Loeb Purchases 7 Stocks in 3rd Quarter GuruFocus.com
04:35PM  Merck Begins Rolling Submission of Licensure Application for V920 (rVSVG-ZEBOV-GP) to U.S. Food and Drug Administration Business Wire
01:17PM  Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates Zacks
Nov-12-18 03:46PM  5 Stocks to Sell After the Midterm Election InvestorPlace
01:19PM  October's biggest Losers And Most Surprising Winners Benzinga
09:44AM  Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer Zacks
06:55AM  FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review Business Wire
Nov-09-18 04:21PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib Business Wire
03:17PM  Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update Zacks
02:23PM  Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag Zacks
06:45AM  New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancers 33rd Annual Meeting Business Wire
Nov-08-18 05:50PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
04:16PM  Endo Plans For Cellulite Drug In 2020 Here's Why Investors Balked Investor's Business Daily
04:14PM  AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' Streak Investor's Business Daily
04:11PM  Jeff Auxier Comments on Biogen GuruFocus.com
11:13AM  Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise Zacks
08:42AM  Merck and Johnson & Johnson Shares Show Big Buying Investopedia
08:14AM  Democrats Hold Edge in House Battle: 5 Great Picks (Revised) Zacks
07:28AM  Endo stock rises 6% after Q3 beats and upbeat 2018 guidance MarketWatch
Nov-07-18 04:08PM  Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View Zacks
12:16PM  'We have a lot of things in common' Trump wants to work with Democrats on infrastructure, drugs CNBC
06:45AM  Early Phase 1 Data from Mercks Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITCs 33rd Annual Meeting Business Wire
Nov-06-18 11:05AM  5 Companies Hit 52-Week Highs GuruFocus.com
07:00AM  Democrats Hold Edge in House Battle: 5 Great Picks Zacks
Nov-05-18 02:20PM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3 Zacks
09:35AM  ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance Zacks
Nov-02-18 06:11PM  AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues Zacks
01:23PM  MARKETS: Now Facebook, J&J, Pfizer and Merck are dragging down the market, while Exxon and Chevron are bright spots Yahoo Finance Video
09:40AM  The Zacks Analyst Blog Highlights: Amazon, Facebook, Mastercard and Merck Zacks
09:07AM  Dow Recovers More Than 900 Points in 3 Days: 5 Top Picks Zacks
08:30AM  New Research Coverage Highlights Landstar System, CMS Energy, MoSys, Pennsylvania Real Estate Investment Trust, Procter & Gamble, and Merck & Co. Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-01-18 04:56PM  Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales Zacks
04:50PM  Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View Zacks
02:33PM  Does Merck & Co Incs (NYSE:MRK) CEO Pay Reflect Performance? Simply Wall St.
01:51PM  Merck CEO on US healthcare system and drug pricing CNBC Videos
10:23AM  Big pharma leases almost 500,000 square feet for new research center American City Business Journals
10:20AM  Edited Transcript of MRK earnings conference call or presentation 25-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
09:55AM  3 Pharma Stocks to Make a Portfolio Feel Better Investopedia
Oct-31-18 02:52PM  The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead Zacks
08:20AM  The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut Benzinga
Oct-30-18 04:09PM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Business Wire
07:06AM  3 Industries to Own if the Stock Market Keeps Falling Motley Fool
Oct-29-18 07:10PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
04:16PM  Biogen And Eisai May Be At Odds In Alzheimer's So What Now? Investor's Business Daily
Oct-26-18 11:39AM  Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO Zacks
09:56AM  Company News For Oct 26, 2018 Zacks
Oct-25-18 04:29PM  Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings TheStreet.com
04:00PM  Stocks snap back after Wednesday's rout Yahoo Finance
03:00PM  Merck & Co., Inc. -- Moody's: Merck's shareholder payouts credit negative Moody's
02:25PM  Pharma Giants Merck, Bristol Diverge On Earnings Beat As Sales Lag Investor's Business Daily
01:57PM  Merck & Co Inc (MRK) Q3 2018 Earnings Conference Call Transcript Motley Fool
11:44AM  Merck and Bristol-Myers Squibb Are Seeing Rising Sales of Their Cancer Drugs Barrons.com
11:26AM  Merck (MRK) Beats on Q3 Earnings, Lags Sales, Ups EPS View Zacks
11:25AM  Former P&Ger joins Merck C-suite American City Business Journals
10:43AM  Merck, Bristol-Myers profits rise on cancer drug sales Reuters
10:31AM  Merck, Bristol-Myers profits rise on cancer drug sales Reuters
10:22AM  Merck posts global sales of $11B in third quarter Associated Press
09:50AM  Merck&Co Earnings beat, Revenue misses In Q3 Investing.com
09:37AM  J&J Intends to Buy Residual Stake in Japanese Skincare Firm Zacks
09:06AM  Merck says to retain animal health business as part of company Reuters
08:53AM  3 Beaten-Down Biotech Stocks: Can They Bounce Back? Motley Fool
08:02AM  Cancer drug Keytruda powers Merck's profit beat, forecast raise Reuters
08:00AM  Merck (MRK) Q3 Earnings Surpass Estimates Zacks
07:21AM  [$$] Merck's 3Q Profit Misses Expectations The Wall Street Journal
07:15AM  Drugmaker Merck beats profit estimate on Keytruda strength Reuters
07:01AM  [$$] Bristol-Myers Squibb Raises Full-Year Profit Forecast The Wall Street Journal
06:59AM  Bristol-Myers profit rises on better-than-expected cancer drug sales Reuters
06:51AM  Merck raises quarterly dividend by 15% to 55 cents a share, unveils $10 billion buyback MarketWatch
06:50AM  Merck reports third-quarter profit vs year-ago loss Reuters
06:46AM  Merck Announces Increased Fourth-Quarter Dividend and $10 Billion Share Repurchase Authorization Business Wire
06:45AM  Merck Announces Third-Quarter 2018 Financial Results Business Wire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. Merck & Co., Inc. has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, Premier Inc., Cue Biopharma, Inc., Foundation Medicine, Inc., and Daiichi Sankyo Company, Limited. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM
WEEKS WENDELL PDirectorFeb 09Option Exercise38.045,000190,2005,100Feb 09 04:48 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthFeb 09Option Exercise0.008,572045,780Feb 09 04:48 PM
WEEKS WENDELL PDirectorFeb 09Sale53.575,000267,833100Feb 09 04:48 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM